Copied
 
 
2022, DKK
07.07.2023
Bruttoresultat

242''

Primær drift

-91.982

Årets resultat

-239''

Aktiver

1.108''

Kortfristede aktiver

1.044''

Egenkapital

1.094''

Afkastningsgrad

-0 %

Soliditetsgrad

99 %

Likviditetsgrad

+500%

Resultat
07.07.2023
Årsrapport
2022
07.07.2023
2021
30.06.2022
2020
28.07.2021
2019
14.09.2020
2018
16.06.2019
2017
01.06.2018
2015
02.06.2017
Nettoomsætning294.160.929249.101.475
Bruttoresultat242.214.866217.228.606000
Resultat af primær drift-91.982-126.942-59.531-57.376-65.664
Indtægter af kapitalandele (tilknyttede og associerede) 00000
Finansielle indtægter10.504.619125.119.27529.173.6086.196.4950
Finansieringsomkostninger00000
Andre finansielle omkostninger-315.247.584-2.107.339-5.961.775-8.886.724-2.592
Resultat før skat-301.645.833468.201.620743.343.45047.570.236-524.985
Resultat-239.094.047439.438.586738.010.54949.537.938-524.985
Forslag til udbytte00000
Aktiver
07.07.2023
Årsrapport
2022
07.07.2023
2021
30.06.2022
2020
28.07.2021
2019
14.09.2020
2018
16.06.2019
2017
01.06.2018
2015
02.06.2017
Kortfristede varebeholdninger29.421.3907.615.023000
Kortfristede tilgodehavender fra salg og tjenesteydelser 67.980.4573.262.388109.685.9941.967.702111.608.353
Likvider3.574.7836.435.2313.196.138243.388252.226
Kortfristede aktiver1.044.316.5071.286.479.649616.952.0402.211.090252.226
Immaterielle aktiver og goodwill24.149.95340.519.76381.039.526117.057.093153.074.660
Finansielle anlægsaktiver63.745.321128.169.543320.183.318347.513.626347.199.562
Materielle aktiver76.457.62977.718.46679.812.74624.860.87218.998.423
Langfristede aktiver63.745.321128.169.543320.183.318347.513.626347.199.562
Aktiver1.108.061.8281.414.649.192937.135.358349.724.716347.451.788
Aktiver
07.07.2023
Passiver
07.07.2023
Årsrapport
2022
07.07.2023
2021
30.06.2022
2020
28.07.2021
2019
14.09.2020
2018
16.06.2019
2017
01.06.2018
2015
02.06.2017
Forslag til udbytte00000
Egenkapital1.094.267.4641.372.296.772931.732.457146.914.08391.145.917
Hensatte forpligtelser0821.185594.66900
Langfristet gæld til banker00000
Anden langfristet gæld00000
Leverandører af varer og tjenesteydelser18.949.35314.868.55110.767.42038.154.67225.123.661
Kortfristede forpligtelser13.794.36442.352.4205.402.901202.810.633256.305.871
Gældsforpligtelser13.794.36442.352.4205.402.901202.810.633256.305.871
Forpligtelser13.794.36442.352.4205.402.901202.810.633256.305.871
Passiver1.108.061.8281.414.649.192937.135.358349.724.716347.451.788
Passiver
07.07.2023
Nøgletal
07.07.2023
Årsrapport
2022
07.07.2023
2021
30.06.2022
2020
28.07.2021
2019
14.09.2020
2018
16.06.2019
2017
01.06.2018
2015
02.06.2017
Afkastningsgrad 0,0 %0,0 %0,0 %0,0 %0,0 %
Dækningsgrad 82,3 %87,2 %Na.Na.Na.
Resultatgrad -81,3 %176,4 %Na.Na.Na.
Varelagerets omsætningshastighed 10,0 32,7 Na.Na.Na.
Egenkapitals-forretning -21,8 %32,0 %79,2 %33,7 %-0,6 %
Payout-ratio Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal Na.Na.Na.Na.Na.
Soliditestgrad 98,8 %97,0 %99,4 %42,0 %26,2 %
Likviditetsgrad 7.570,6 %3.037,6 %11.418,9 %1,1 %0,1 %
Resultat
07.07.2023
Gæld
07.07.2023
Årsrapport
07.07.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 07.07.2023)
Information om virksomhedens regnskabsklasse:This annual report has been prepared in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium).
Beretning
07.07.2023
Dato for ledelsens godkendelse af årsrapporten:2023-07-06
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Executive Board has today considered and approved the annual report of NB Herlev Holding ApS for the financial year 01. 01. 2022 - 31. 12. 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesThe activities of the Parent Company comprise shareholdings in other companies and related activity. The most material investment is in Nordic Bioscience Holding A/S which carry out research and development within the pharmaceutical sector. The group's business activities The Group was established in 2018 when the Company acquired the majority interest in Nordic Bioscience Holding A/S. The main activities of the group are research and development within the pharmaceutical sector. The research and development are performed both for own and for third parties on contract basis and consist of both clinical and preclinical research. For a more detailed description we refer to the consolidated financials of Nordic Bioscience Holding A/S